周五盘中，生物技术巨头莫德纳（Moderna, Inc.，股票代码：MRNA）股价出现显著上涨，涨幅高达5.69%，引发市场广泛关注。
根据最新交易数据，莫德纳股价报24.84美元/股，成交量达393.8万股，换手率为1.02%，振幅4.93%。这一强劲表现与整个生物技术行业0.45%的涨幅形成鲜明对比，凸显了投资者对莫德纳未来发展前景的信心。
值得注意的是，尽管莫德纳最近的财报显示净亏损9.71亿美元，每股亏损2.52美元，但机构投资者对该公司仍保持谨慎乐观态度。在29家参与评级的机构中，21%给予买入建议，66%建议持有，仅13%建议卖出。作为mRNA技术的领先企业，莫德纳在新冠疫情期间迅速崛起，目前拥有40个处于临床试验阶段的mRNA开发候选物，涵盖传染病、肿瘤学、心血管疾病和罕见遗传病等多个治疗领域，显示出公司在生物技术创新方面的持续实力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.